SHORT COMMUNICATION

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock

AC West1,2,3, BP Martin1, DA Andrews4, SJ Hogg1,5, A Banerjee2,6, G Grigoriadis2,7,8,9, RW Johnstone1,5,10 and J Shortt1,5,8,9,10

Inhibitor of apoptosis proteins (IAPs) antagonize caspase activation and regulate death receptor signaling cascades. LCL-161 is a small molecule second mitochondrial activator of caspase (SMAC) mimetic, which both disengages IAPs from caspases and induces proteasomal degradation of cIAP-1 and -2, resulting in altered signaling through the NFκB pathway, enhanced TNF production and sensitization to apoptosis mediated by the extrinsic pathway. SMAC mimetics are undergoing clinical evaluation in a range of hematological malignancies. Burkitt-like lymphomas are hallmarked by a low apoptotic threshold, conveying sensitivity to a range of apoptosis-inducing stimuli. While evaluating LCL-161 in the Eμ-Myc model of aggressive Burkitt-like lymphoma, we noted unexpected resistance to apoptosis induction despite ‘on-target’ IAP degradation and NFκB activation. Moreover, LCL-161 treatment of lymphoma-bearing mice resulted in apparent disease acceleration concurrent to augmented inflammatory cytokine-release in the same animals. Indiscriminate exposure of lymphoma patients to SMAC mimetics may therefore be detrimental due to both unanticipated prolymphoma effects and increased susceptibility to endotoxic shock.

Oncogenesis (2016) 5, e216; doi:10.1038/oncsis.2016.26; published online 4 April 2016

INTRODUCTION

Inhibitor of apoptosis proteins (IAPs) (X-linked IAP, cIAP1 and cIAP2) possess baculoviral IAP repeat (BIR) domains that mediate binding to post-mitochondrial caspases.1 Mitochondrial permeabilization releases second mitochondrial activator of caspases (SMAC), which competes for BIR occupancy on IAPs to augment apoptosis induction. Accordingly, the initial basis for development of small molecule SMAC mimetics as antineoplastics was as simple proapoptotic agents. It was subsequently demonstrated that IAP antagonists induce proteasomal degradation of cIAP1 and cIAP2, enhancing both canonical and noncanonical NFκB signaling downstream of tumor necrosis factor (TNF) family receptors concurrent to the initiation of autocrine death receptor (DR) signaling.2,3 Susceptible cell lines are exclusively sensitive to IAP antagonists due to feedback amplification of the extrinsic apoptotic pathway, mediated primarily by TNFα.

LCL-161 (Novartis, Basel, Switzerland) is an orally available IAP antagonist with preclinical activity as a single agent demonstrated in multiple myeloma,4 glioblastoma5 and sarcoma.5,6 In the absence of single-agent activity, LCL-161 sensitizes to apoptosis induction by chemotherapy or BCL-2 inhibition in hepatocellular carcinoma7,8 and radiotherapy in esophageal carcinoma.9 Synergistic activation of the extrinsic apoptotic pathway was also demonstrated by combining LCL-161 with adenosine-5’-monophosphate-induced TNFα in melanoma.10 The results of a phase I dose escalation study were recently reported.11 Despite biomarkers on in vivo cIAP1 degradation and cytokine release at well-tolerated doses, no objective responses were observed in the solid organ tumor setting. However, clinical trials with LCL-161 and other SMAC mimetics are ongoing, including in hematological malignancies such as multiple myeloma and acute myeloid leukemia.

Lymphomas driven by the cMYC oncogene are remarkable for high rates of basal proliferation and apoptosis. cIAP1 potentiates MYC activity, by ubiquitinating its negative regulator, MXD1.12 We therefore hypothesized that LCL-161 would show potent activity in the Eμ-Myc model of aggressive lymphoma, which is sensitive to a range of novel apoptosis-inducing stimuli.13-16 Unexpectedly, Eμ-Myc lymphomas were highly resistant to LCL-161-induced apoptosis in vitro, despite engagement of IAP degradation and NFκB activation at ‘on-target’ concentrations. Moreover, LCL-161 did not sensitize Eμ-Myc lymphomas to death-receptor-induced apoptosis. Interestingly, LCL-161 treatment of lymphoma-bearing mice accelerated disease progression culminating in a survival disadvantage compared with vehicle-treated controls. Analogous to the cytokine release syndrome (CRS) encountered in human trials,17 LCL-161 markedly exacerbated inflammatory cytokine-release following lipopolysaccharide (LPS) challenge. Thus, LCL-161 accelerates Eμ-Myc lymphoma and...
lymphomas following the 24 h LCL-161 treatment at low μ was readily degraded in three independently-derived E100-fold dose escalation (Figure 2a). LCL-161 at corresponding concentrations and even with a lymphoma cells were resistant to apoptosis induction by μ the LCL-161 treatment. However, despite biochemical evidence of dation to correlate with a potent apoptotic response following fi mouse embryo were observed in human breast cancer cells (MDA-MB-231) and whether cIAP1 degradation induced downstream NF κB signaling downstream of TNF family receptors concurrent to 6 We therefore expected IAP degra- cIAP1 and cIAP2, enhancing both canonical and noncanonical NFκB signaling downstream of TNF family receptors concurrent to the initiation of autocrine DR signaling.1,2,3 We first investigated the capacity of LCL-161 to induce cIAP1 degradation in vitro. cIAP1 was readily degraded in three independently-derived E-μ-My- Myc lymphomas following the 24 h LCL-161 treatment at low concentrations (0.2–2 μM). Similar levels of cIAP1 degradation were observed in human breast cancer cells (MDA-MB-231) and mouse embryo fibroblasts (MEF; Figure 1a). Next, we investigated whether cIAP1 degradation induced downstream NFκB activation in E-μ-Myc cells. Upon treatment with LCL-161 or stimulation with TNFα, the NFκB subunit p65 was phosphorylated in E-μ-My- Myc lymphomas (Figure 1b). Similar phosphorylation of p65 in response to LCL-161 was observed in additional nonhematopoie- tic cancer cell lines (MDA-MB-231 and HT1080), even though these were relatively insensitive to TNFα stimulation (Figure 1b). Thus, E-μ-Myc lymphoma exhibited degradation of cIAP1 and NFκB pathway activation in response to LCL-161 in vitro.

E-μ-Myc lymphoma is resistant to apoptosis induction by LCL-161. Similar to human MYC-driven lymphomas, E-μ-Myc lymphoma is sensitive to apoptosis induction by a range of novel and conventional therapeutics.1,3–16 We therefore expected IAP degra- dation to correlate with a potent apoptotic response following the LCL-161 treatment. However, despite biochemical evidence of LCL-161-mediated cIAP1 degradation (Figure 1a), E-μ-Myc lymphoma cells were resistant to apoptosis induction by LCL-161 at corresponding concentrations and even with a 100-fold dose escalation (Figure 2a).

Apoptosis induction by IAP antagonists is primarily mediated by autocrine DR signaling via TNFα.2,3 We therefore assessed the capacity of E-μ-Myc lymphoma cells to either secrete or respond to TNFα in response to LCL-161. TNFα was not detected upon assessment of the supernatant of LCL-161-treated E-μ-Myc cells by cytokine bead array (data not shown). However, exogenous TNFα induced p65 phosphorylation indicating intact TNF receptor activity (Figure 1b). We therefore assessed the capacity for LCL-161 to augment an apoptotic response to exogenous TNFα. E-μ-Myc cells were treated with LCL-161 in the presence of increasing TNFα concentrations (Figure 2b). Neither TNFα alone, nor the addition of TNFα to LCL-161 resulted in apoptosis of E-μ-Myc lymphoma cells, despite robust apoptosis induction in the MDA-MB-231 (LCL-161-sensitive control) treated concurrently (Figure 2b).

E-μ-Myc lymphoma is resistant to apoptosis induction by DR agonists
Given the lack of TNFα-induced cell death in E-μ-Myc cells, we next sought to determine if E-μ-Myc cells were capable of undergoing apoptosis in response to direct stimulation of the extrinsic apoptosis pathway. Surface expression of DR-5 was detected on E-μ-Myc lymphoma cells, albeit in low levels (Figure 2c). However, E-μ-Myc lymphoma cells were resistant to the DR-5 agonistic antibody, M5.1, administered alone or in combination with LCL-161 (Figure 2d). In contrast, M5.1 readily induced apoptosis in the 4T1.2 murine breast cancer cell line. Together these data suggest E-μ-Myc lymphoma is resistant to LCL-161, despite cIAP1 degradation and NFκB engagement due to insensitivity to extrinsic apoptotic stimuli, and a subsequent failure to engage autocrine DR signaling described in other models.2,3

LCL-161 reduces the survival of mice bearing E-μ-Myc lymphoma
The absence of an in vitro apoptotic response to LCL-161 does not necessarily preclude in vivo activity. For example, non-tumor cell autonomous mechanisms of action including paracrine signaling, microenvironmental changes and the host immune response may be important mediators of therapeutic responses in the absence of direct apoptosis induction. Indeed, we have previously

---

**Figure 1.** LCL-161 induces cIAP degradation and NFκB at on-target concentrations in vitro. (a) C57Bl/6-derived E-μ-Myc lymphomas (107, 4242 and 6066 derived and maintained as described previously1,2) as well as MDA-MB-231 and MEF control cells (cultured in DMEM with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine and penicillin (100 U/ml)/streptomycin (100 μg/ml); all Gibco, ThermoFisher Scientific, Waltham, MA, USA at 37 °C and 5% CO2) were treated with increasing doses of LCL-161 (0.2 or 2 μM for 24 h; kindly provided by Novartis) or vehicle control. cIAP1 expression was assessed on protein lysates by western blot using standard techniques and antibodies against cIAP1 (#4952; Cell Signaling Technology, Danvers, MA, USA) and actin (#A2228; Sigma-Aldrich, St Louis, MO, USA) to confirm equivalent loading. (b) E-μ-Myc (4242 and 107) lymphomas, MDA-MB-231 and HT1080 cells were treated with LCL-161 (2 μM) and/or TNFα (2.5 ng/ml; R&D Biosystems, Minneapolis, MN, USA) for 2 h, and NFκB activation assessed by western blotting using antibodies against phosphorylated (Ser536) p65 (93H1 #3033; Cell Signaling Technology), total p65 (#ab7970; Abcam, Cambridge, UK) and then reprobed for tubulin (#T5326; Sigma-Aldrich) to confirm equivalent loading. Images shown are representative of three biological replicates.
demonstrated that an intact host immune system is required for optimal responses to other novel antilymphoma agents in vivo. We therefore assessed the response of the same lymphomas (presented in Figure 1) in an in vivo syngeneic transplant setting, utilizing immunocompetent wild-type C57Bl/6 mice. Although we did not necessarily anticipate efficacy (given our in vitro findings), unexpectedly worse outcomes were demonstrated for LCL-161-treated mice compared with vehicle controls in the majority of experiments performed (Figure 3a). We observed a reduction in the median survival of mice transplanted with two independently-derived lymphomas (107 and 6066) and treated with LCL-161 (Figure 3a). Either no significant benefit, or a reduction in survival was observed with the third lymphoma (4242) in independent experiments. Premature death was attributable to progressive lymphoma, rather than drug toxicity, as evidenced by equivalent tumor burden (spleen weight) observed in LCL-161-treated mice at end point compared with vehicle-treated mice when they succumbed to lymphoma (Figure 3b). Furthermore, an increased proportion of lymphoma cells in leukemic phase (Figure 3c) and subtly increased lymphoma burden by luciferase reporter imaging was observed in LCL-161-treated mice during treatment (Figure 3d).

Figure 2. Eµ-Myc lymphomas are refractory to apoptosis via LCL-161 and the extrinsic apoptosis pathway. (a) Eµ-Myc lymphomas (4242 and 107; 1–10 × 10⁵) were treated with LCL-161 (0.2, 2 or 20 μM) or vehicle control (−) and assessed for apoptosis by flow cytometry at 24 and 48 h using Annexin-V (#17-8007; eBiosciences, San Diego, CA, USA) and viability dye (Fluoro-Gold; Fluorochrome, LLC, Denver, CO, USA) staining. (b) Eµ-Myc lymphomas (4242 and 107) and MDA-MB-231 cells (MDA) were treated with LCL-161 or vehicle control (as per a) in the presence of increasing doses of TNFα and assessed for apoptosis by flow cytometry after 24 or 48 h using Annexin-V and viability dye staining as described in a. (c) The surface expression of DR-5 on live Eµ-Myc 4242 cells was assessed by flow cytometry using an anti-DR-5 antibody (MD5-1; #119905; BioLegend, San Diego, CA, USA) or isotype control (HTK888; 400907; BioLegend) and viability dye staining. (d) Eµ-Myc 4242 (left panel) or 4T1.2 (right panel) cells were treated with plate-bound (8-well Protein A-coated strips; ThermoFisher, Waltham, MA, USA) MD5.1 at the concentrations indicated or isotype control (10 μM; UC8-189; both prepared as previously described31 alone or in combination with LCL-161 (2 μM). Apoptosis was assessed after 24 h treatment by flow cytometry using Annexin-V and viability dye staining as described in a. Error bars represent the mean ± s.e.m. of at least three independent experiments.
LCL-161 treatment can accelerate the progression of Eμ-Myc lymphomas in vivo resulting in reduced survival in lymphoma-bearing mice.

cIAP1 and 2 have previously been implicated as tumor suppressors for human B-cell malignancies,\(^1\) and deletion of these genes was shown to promote B-cell survival in the absence of BAFF-R signaling.\(^1\) Cooperation between MYC and NFκB is also well described in lymphomagenesis\(^2\) and constitutive NFκB activity is a known driver of mature B-cell malignancies where ‘oncogenic addiction’ to NFκB has been reported.\(^2\) Thus, we posit that LCL-161-mediated degradation of cIAP1 and 2 in the absence of an extrinsic apoptotic response may induce B-cell survival signals including NFκB activation, thus supporting Eμ-Myc lymphoma progression in vivo, although the suppression of MYC-driven lymphomagenesis by NFκB activation has also been described.\(^2\)

**Figure 3.** LCL-161 accelerates the progression of Eμ-Myc lymphoma in vivo. (a) Eμ-Myc lymphoma cells were endowed with either GFP or GFP and luciferase expression by routine retroviral techniques using the MSCV-IRES-GFP and MSCV-IRES-Luc vectors, respectively.\(^3\) Next, \(5 \times 10^5\) Eμ-Myc lymphoma cells 107MSCV.GFP (n = 9 per group; left upper panel), 6066MSCV.GFP-Luc (n = 10 vehicle, n = 9 LCL-161; right upper panel), 4242MSCV.GFP, expt 1 (n = 6 vehicle; n = 9 LCL-161; left lower panel) or 4242MSCV.GFP-Luc, expt 2 (n = 9 vehicle; n = 10 LCL-161; right lower panel) were transplanted into syngeneic C57Bl/6 mice (6–12 weeks of age; The Walter and Eliza Hall Institute, Melbourne, VIC, Australia) via tail vein injection. Three days post transplantation, mice were treated with LCL-161 (75 mg/kg) or vehicle control (buffered sodium acetate solution) by oral gavage twice weekly. Mice were killed and autopsied at an end point defined by symptomatic disseminated disease. Kaplan–Meier survival curves are shown. (b) Spleen weights at end point for the respective cohorts of mice as described in a. (c) Percentage of GFP-positive lymphoma cells in peripheral blood of mice receiving either vehicle control or LCL-161 treatment (as per a) as assessed by flow cytometry. Peripheral blood was sampled 8 or 11 days post injection with Eμ-Myc 107MSCV.GFP or 4242MSCV.GFP (expt 2) lymphoma, respectively (as described in a). (d) Bioluminescence imaging was performed using the Xenogen IVIS platform (Caliper Life Sciences, Waltham, MA, USA) and Living Image software (version 2.5, Xenogen). 100 µl of 1.5 mg/ml D-luciferin substrate (ThermoFisher) was administered by intraperitoneal (i.p.) injection to mice prior to anesthetizing with isoflurane and image acquisition. Representative images of mice treated with vehicle alone or LCL-161 on day 7 post receipt of Eμ-Myc 6066MSCV.GFP-Luc lymphoma cells (as per a) are shown. Error bars represent mean ± s.e.m. with sample size chosen to ensure adequate power based on previous publications.\(^1\)–\(^4\) \(*P < 0.05; \text{NS, not significant using Student’s two-tailed unpaired t-test to compare the means of vehicle vs drug-treated groups, and log-rank analysis was used for comparison of survival curves. All mouse experiments were in full compliance with the Peter MacCallum Cancer Centre Animal Ethics Committee.**
LCL-161 reduces survival in B-cell lymphoma
AC West et al

Figure 4. LCL-161 induces cytokine release in lymphoma-bearing mice and exacerbates the response to lipopolysaccharide challenge in vivo. (a) Mouse serum was interrogated for TNFα using the BD Cytometric Cytokine Bead Array mouse Flex Set and Cell Signaling Master Buffer Set (BD Biosciences, Franklin Lakes, NJ, USA) as per the manufacturer's instructions. C57Bl/6 mice (6–12 weeks of age; The Walter and Eliza Hall Institute of Medical Research) shown were transplanted with Eμ-Myc 107/MSCV.GFP lymphoma and treated with two doses of LCL-161 (75 mg/kg; n = 9) or vehicle (n = 8 vehicle) in the week following transplantation (described in Figure 3a). Serum was sampled 18 h after the second dose. (b) Serum was obtained from mice bearing Eμ-Myc 107/MSCV.GFP lymphoma and treated with LCL-161 (n = 3) or vehicle control (described in Figure 3a; n = 3) at the time of killing owing to end-stage lymphoma progression and TNFα levels assessed as in a. (c) Non-tumor-bearing C57Bl/6 mice were pretreated with a single 75 mg/kg dose LCL-161 (n = 5) or vehicle control (n = 4) 4 h prior to administration of LPS (E. coli 0127:B8, gamma-irradiated; Sigma-Aldrich) by i.p injection, 4 h prior to collection of serum. TNFα and IL-6 levels in the sampled serum was assessed as per a. Error bars represent mean ± s.e.m. with sample size chosen to ensure adequate power based on previous publications. *P < 0.05; NS, not significant using a Student's two-tailed unpaired t-test to compare the means of vehicle vs drug-treated groups. All mouse experiments were in full compliance with the Peter MacCallum Cancer Centre Animal Ethics Committee.

Disease acceleration has been reported with other small molecule therapeutics, most notably BRAF inhibitors causing ‘on-target’ acceleration of RAS-mutant squamous cell carcinomas and chronic leukemia.27 Although no tumor regressions were documented in the phase 1 LCL-161 study (of 53 patients), no tumor acceleration was recorded either. As the default interpretation in nonresponders is usually a lack of efficacy, an active detrimental effect (i.e., disease acceleration) may be underappreciated by investigators. Thus, our data provide a cautionary tale to the interpretation of such studies, whereby the investigational agent may promote the progression of certain tumors.

LCL-161 exacerbates the cytokine storm of LPS challenge LCL-161 induces CCL2, IL-10 and TNFα secretion in vivo.11 Both CCL2 and IL-10 have stimulatory effects on the growth and survival of B-cell lymphomas.28,29 Furthermore, in the recently reported phase I clinical trial of LCL-161 in solid organ malignancies, CRS was described as the main dose-limiting toxicity.11 Increases in TNFα and other inflammatory cytokines peaked within 24 h of human LCL-161 administration. Indeed, similar cytokine (TNFα release) was detectable in lymphoma-bearing mice following LCL-161 dosing (Figure 4a), indicating accelerated lymphoma progression occurred in the context of changes to the cytokine milieu. However, the absolute serum TNFα levels were relatively low and not differentially elevated in mice at the time of killing, indicating that premature deaths were unlikely to have resulted from CRS (Figure 4b).

To further evaluate the propensity for IAP antagonists to augment CRS, we next administered LCL-161 to non-tumor-bearing C57Bl/6 mice prior to activation of inflammatory NFκB signaling by injection of a sublethal LPS challenge. The induction of inflammatory cytokines (TNFα and IL-6) in mice challenged with LPS was markedly increased in the presence of LCL-161 (Figure 4c) to the extent that LCL-161 (and not untreated mice) required killing due to endotoxemia 4 h after injection. These data confirm LCL-161 is pharmacologically active in mice at the doses used in lymphoma experiments. Moreover, LCL-161 has the capacity to broadly synergize with inflammatory stimuli and can cooperate in the induction of endotoxic shock in vivo.

LCL-161 was recently described as a ‘double-edged sword’ in cancer therapy, due to its propensity to induce cytokine release.30 We demonstrated similar cytokine release following dosing of lymphoma-bearing mice, although it did not constitute a dose-limiting toxicity. However, LCL-161 augmented a lethal CRS post LPS challenge indicating a further potential clinical risk with SMAC mimetics. Cancer patients are often immunosuppressed due to underlying disease or prior therapies, particularly those with bone marrow dysfunction due to hematological malignancy. Those patients developing bacterial infections while on IAP-inhibitor therapy are likely to be particularly susceptible to septic shock, again calling for clinical vigilance and a low threshold for drug discontinuation during active infection. The notion of this ‘double-edged sword’ whereby SMAC mimetics may be detrimental to patients is indeed reinforced by our data, indicating the potential for both disease acceleration and increased susceptibility to endotoxemia. The clinical translation of IAP antagonists requires close monitoring to avoid adverse patient outcomes. In conclusion, we suggest that the use of SMAC mimetics to treat lymphoma should be carefully rationalized according to activity of specific molecular pathways where possible.

CONFLICT OF INTEREST
LCL-161 was provided by Novartis. RJ has received honoraria and attended advisory boards for Novartis. JS has received travel sponsorship and attended advisory boards for Novartis. The other authors have no relevant conflicts of interest to declare.

ACKNOWLEDGEMENTS
ACW was supported by the Cancer Council of Victoria (CCV). SJH is funded by the Leukaemia Foundation of Australia (LFA). JS is supported by funding from the CCV, LFA, Eva & Les Endi/Snowdome Foundation and Victorian Cancer Agency (VCA). RWJ is a Senior Principal Research Fellow of the National Health & Medical Research Council of Australia (NHMRC) and is supported by NHMRC Program and Project Grants, the CCV and VCA. GG is a VCA Clinical Research Fellow. DAA is supported by an NHMRC Career Development Fellowship.

REFERENCES
1 Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6: 287–297.
2 Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007; 131: 682–693.
3 Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFα-dependent apoptosis. Cell 2007; 131: 669–681.
4 Ramakrishnan V, Painuly U, Kimlinger T, Haug J, Rajkumar SV, Kumar S. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia 2014; 28: 1519–1528.
LCL-161 reduces survival in B-cell lymphoma
AC West et al.

17 West AC, Mattarollo SR, Steegh K, Duret H, Martin B, Cunningham J, Martin A, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012; 120: 3019–3029.

20 Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 2010; 9: 97.

21 Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115–130.

22 Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131–144.

23 Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B-cell-like diffuse large B-cell lymphoma cells. J Exp Med 2001; 194: 1861–1874.

24 Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C et al. Myc suppression of NFkbeta accelerates lymphomagenesis. BMC Cancer 2010; 10: 348.

25 Clapproth K, Sander S, Marinkovic D, Baumann B, Wirth T. The IKK2/NF-(kappa)B pathway suppresses MYC-induced lymphomagenesis. Blood 2009; 114: 2448–2458.

26 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–2516.

27 Callahan MK, Rampal R, Harding JJ, Klimkew T et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012; 367: 2316–2321.

28 Burgess M, Cheung C, Chambers L, Ravindranath K, Minhas G, Knop L et al. CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma 2012; 53: 1988–1998.

29 Gupta M, Han JJ, Stenson M, Maurer M, Wellick L, Hu G et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844–2853.

30 Fulda S. Targeting inhibitor of apoptosis proteins for cancer therapy: a double-edge sword? J Clin Oncol 2014; 32: 3190–3191.

31 Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199: 437–448.

32 Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012; 120: 3019–3029.
